Compare ATRA & ONMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATRA | ONMD |
|---|---|---|
| Founded | 2012 | 2006 |
| Country | United States | United States |
| Employees | N/A | 23 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.9M | 35.9M |
| IPO Year | 2014 | N/A |
| Metric | ATRA | ONMD |
|---|---|---|
| Price | $9.43 | $0.74 |
| Analyst Decision | Sell | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | 75.0K | ★ 352.0K |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 122.52 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $120,772,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.92 | $0.44 |
| 52 Week High | $19.15 | $4.22 |
| Indicator | ATRA | ONMD |
|---|---|---|
| Relative Strength Index (RSI) | 43.33 | 55.45 |
| Support Level | $9.03 | $0.59 |
| Resistance Level | $11.17 | $0.96 |
| Average True Range (ATR) | 0.80 | 0.07 |
| MACD | -0.24 | 0.02 |
| Stochastic Oscillator | 0.00 | 91.30 |
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).
OneMedNet Corp is a healthcare software company with solutions focused on digital medical image management, exchange, and sharing. It is a provider of clinical imaging innovation and curator of regulatory-grade Imaging Real World Data(iRWDTM). Its solutions connect healthcare providers and patients, satisfying a crucial need within the life sciences field, offering direct access to clinical images and the associated contextual patient record. Its technology has provens the commercial and regulatory viability of imaging Real World Data, an emerging market, and provides regulatory-grade, image-centric iRWDTM. Geographically, it operates in Americas, Europe and Middle East, and Asia Pacific. It derives maximum revenue from Europe and Middle East.